论文部分内容阅读
使用生物活性检测法检测ATRA治疗前后APL患者血清中IL-1活性的动态变化,并分析IL-1活性与外周血白细胞数变化的相关性。观察经ATRA作用后不同时相NB4细胞、巨噬细胞和血管内皮细胞上清液中IL-1活性的动态变化,并以RT-PCR法检测NB4细胞中IL-1 mRNA表达的变化。结果表明,患者外周血白细胞数及粒细胞数与血清中IL-1活性的变化相关;ATRA作用后,NB4细胞、巨噬细胞和血管内皮细胞上清液中IL-1活性均呈时间依赖性增高;ATRA可上调NB4细胞中IL-1的表达。结论:ATRA治疗APL过程中,多种细胞来源的IL-1可能参与了高白细胞症的发生。
The activity of IL-1 in sera of patients with APL before and after ATRA treatment was detected by bioassay, and the correlation between IL-1 activity and leukocyte count in peripheral blood was analyzed. The dynamic changes of IL-1 activity in NB4 cells, macrophages and vascular endothelial cells supernatant were observed after ATRA treatment. The expression of IL-1 mRNA in NB4 cells was detected by RT-PCR. The results showed that the number of leukocytes and the number of granulocytes in peripheral blood were correlated with the changes of serum IL-1 activity. After ATRA treatment, the activities of IL-1 in NB4 cells, macrophages and vascular endothelial cells supernatant were time-dependent ATRA can upregulate the expression of IL-1 in NB4 cells. Conclusion: ATRA treatment of APL, a variety of cell-derived IL-1 may be involved in the occurrence of leukemia.